论文部分内容阅读
目的观察盐酸吡格列酮治疗早期糖尿病肾病的临床疗效和安全性。方法随机选取早期糖尿病肾病(DN)50例,在原降糖方案基础上加用盐酸吡格列酮30mg/d,治疗12周,观察治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、C-反应蛋白(CRP)、24h尿白蛋白排泄率(UAER)的变化,同时观察药物不良反应。结果患者FPG、HbA1c、TG、LDL-C、UAER、CRP下降及HDL-C上升,具有统计学差异(P<0.05);不良反应有低血糖症(1例)、下肢水肿(1例),无严重不良反应。结论盐酸吡格列酮治疗早期糖尿病肾病安全、有效。
Objective To observe the clinical efficacy and safety of pioglitazone hydrochloride in the treatment of early diabetic nephropathy. Methods Fifty patients with early diabetic nephropathy (DN) were randomly selected and treated with pioglitazone 30 mg / d on the basis of the original hypoglycemic regimen for 12 weeks. The levels of fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG), glycosylated hemoglobin HbA1c, TC, TG, LDL-C, HDL-C, C-reactive protein (CRP) and urinary albumin excretion rate 24h UAER) changes, while observing adverse drug reactions. Results The levels of FPG, HbA1c, TG, LDL-C, UAER, CRP and HDL-C increased with statistical significance (P <0.05) No serious adverse reactions. Conclusion Pioglitazone hydrochloride is safe and effective in the treatment of early diabetic nephropathy.